Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing new data available from ASCO 2023 on MDS with a focus on Bristol Myers' Reblozyl (luspatercept) COMMANDS trial and Geron's imetelstat IMerge Phase 2/3 study in patients with LR-MDS.

Ticker(s): BMY, GERN

Who's the expert?

Institution: Pinehurst Medical Clinic

Hematology oncology physician at Pinehurst Medical Clinic serving patients at FirstHealth Outpatient Cancer Center located in Pinehurst North Carolina.
Currently treats 30 patients with LR-MDS and also treats patients with Tazverik.
Specializes in diagnosing and treating cancer and blood disorders: Anemia, Aplastic Anemia/Bone Marrow Failure, Bleeding Disorders, Bone Marrow/Stem Cell Transplantation, Leukemia, Low Platelet Counts, Low White Blood Cell Counts, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes.

Interview Goal

This discussion will focus on MDS, specifically the new data available from ASCO 2023 from the Phase 3 COMMANDS trial comparing the efficacy and safety of Bristol Myers' luspatercept vs epoetin alfa in patients with transfusion dependent LR-MDS and from the Phase 2/3 IMerge trial evaluating Geron's imetelstat in patients with transfusion dependent LR-MDS.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.